




PHARMACEUTICAL 2023

Biostax Corp.
Rank 419 of 446





PHARMACEUTICAL 2023

Biostax Corp.
Rank 419 of 446



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 251% points.

The company's Economic Capital Ratio, given in the ranking table, is -354%, being 397% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	150
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,477
Liabilities, Non-Current	0
Other Assets	813
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,373
Other Revenues	0
Property and Equipment	0
Research and Development	14
Selling, General and Administrative Expense	1,149

Output Variable	Value in 1000 USD
Assets	964
Liabilities	3,477
Expenses	1,163
Revenues	0
Stockholders Equity	-2,513
Net Income	-3,536
Comprehensive Net Income	-3,536
Economic Capital Ratio	-354%